

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 207/00, 211/78, 215/00, 233/00, 233/22, 273/00, 307/02, 333/22, 403/02, 409/00, 471/02		A1	(11) International Publication Number: WO 96/00212 (43) International Publication Date: 4 January 1996 (04.01.96)
(21) International Application Number: PCT/US95/08213 (22) International Filing Date: 27 June 1995 (27.06.95) (30) Priority Data: 08/265,656 27 June 1994 (27.06.94) US 08/390,641 17 February 1995 (17.02.95) US 08/454,600 31 May 1995 (31.05.95) US 08/454,748 31 May 1995 (31.05.95) US (71) Applicant: CYTOMED, INC. [US/US]; 840 Memorial Drive, Cambridge, MA 02139 (US). (72) Inventors: CAI, Xiong; 3 Marian Road, Framingham, MA 01701 (US). GREWAL, Grewal; 2 Course Brook Lane, Natick, MA 01760 (US). HUSSOIN, Sajjat; 61 Laconia Street, Lexington, MA 02173 (US). FURA, Aberra; Apartment #1707, 812 Memorial Drive, Cambridge, MA 02139 (US). SCANNELL, Ralph; 6 Cider Mill Road, Hopkinton, MA 01748 (US). BIFTU, Tesfaye; 108 Hyslip Street, Westfield, NJ 07090 (US). QIAN, Changgeng; 29 East Plain Street, Wayland, MA 01778 (US). (74) Agents: ZALESKY, Cheryl, K. et al.; Kilpatrick & Cody, Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309-4530 (US).		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, <u>SG</u> , SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published With international search report. 86 9612302-1 (1) PCTA1 & SR (2) Replacement dd 27-12-97	
(54) Title: COMPOUNDS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR, INFLAMMATORY AND IMMUNE DISORDERS			
(57) Abstract Tetrahydrofurans, tetrahydrothiophenes, pyrrolidines and cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. It has been determined that 5-lipoxygenase activity, oral availability, and stability <i>in vivo</i> (for example, glucuronidation rate) can vary significantly among the optical isomers of the disclosed compounds.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

9612302-1